Novavax (NVAX) Misses Q3 EPS, Revenue Beats; Guides to Low End
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts NVAX Hot Sheet
Join SI Premium – FREE
Novavax (NASDAQ: NVAX) reported Q3 EPS of ($2.15), $3.78 worse than the analyst estimate of $1.63. Revenue for the quarter came in at $735 million versus the consensus estimate of $623.9 million.
GUIDANCE:
Novavax sees FY2022 revenue of $2 billion, versus the consensus of $2.04 billion.
For earnings history and earnings-related data on Novavax (NVAX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- MFA Financial (MFA) Misses Q3 EPS by 2c
- Flutter Entertainment plc (FLUT) Misses Q3 EPS by 525c; lowers guidance
- Harmony Biosciences (HRMY) Misses Q3 EPS by 30c; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
